Cargando…
Comparative molecular docking and simulation analysis of molnupiravir and remdesivir with SARS-CoV-2 RNA dependent RNA polymerase (RdRp)
Treatment of SARS-CoV-2 targeting its RNA dependent RNA polymerase (RdRp) is of current interest. Remdesivir has been approved for the treatment of COVID-19 around the world. However, the drug has been linked with pharmacological limitations like adverse effects and reduced efficiency. Nevertheless,...
Autores principales: | Patil, Shashank M, Maruthi, KR, Bajpe, Shrisha Naik, Vyshali, VM, Sushmitha, S, Akhila, Chagalamari, Ramu, Ramith |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Biomedical Informatics
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148593/ https://www.ncbi.nlm.nih.gov/pubmed/35655903 http://dx.doi.org/10.6026/97320630017932 |
Ejemplares similares
-
RdRp inhibitors and COVID-19: Is molnupiravir a good option?
por: Hashemian, Seyed Mohammad Reza, et al.
Publicado: (2022) -
Mechanistic insight on the remdesivir binding to RNA-Dependent RNA polymerase (RdRp) of SARS-cov-2
por: Arba, Muhammad, et al.
Publicado: (2021) -
RdRp or RT, That is the Question
por: Peyambari, Mahtab, et al.
Publicado: (2021) -
In silico investigation to identify potential small molecule inhibitors of the RNA-dependent RNA polymerase (RdRp) nidovirus RdRp-associated nucleotidyltransferase domain
por: Pitsillou, Eleni, et al.
Publicado: (2021) -
Evaluation of potential anti-RNA-dependent RNA polymerase (RdRP) drugs against the newly emerged model of COVID-19 RdRP using computational methods
por: Poustforoosh, Alireza, et al.
Publicado: (2021)